Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp. BCTXW


Primary Symbol: T.BCT Alternate Symbol(s):  BCTX

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II... see more

Recent & Breaking News (TSX:BCT)

BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance

GlobeNewswire November 13, 2017

BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™

GlobeNewswire November 6, 2017

FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax™ in Patients with Advanced Breast Cancer

GlobeNewswire October 30, 2017

BriaCell Adds Third Clinical Site – Led by Top Physician-Scientist Dr. Lukas – To Expand Phase I/IIa Clinical Trial in Advanced Breast Cancer

GlobeNewswire September 25, 2017

BriaCell Provides Research Update

GlobeNewswire September 14, 2017

BriaCell Provides A Corporate Update

GlobeNewswire September 12, 2017

BriaCell Announces Additional Capital Support by the CEO

Marketwired August 2, 2017

BriaCell Appoints Top Oncologist and Opens Second Clinical Site for its Ongoing Clinical Trial in Advanced Breast Cancer

Marketwired July 31, 2017

BriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals

Marketwired July 24, 2017

BriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer

Marketwired July 19, 2017

BriaCell Completes Manufacturing of New Batch of BriaVax(TM)

Marketwired July 5, 2017

BriaCell Doses Second Patient in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer

Marketwired June 1, 2017

BriaCell Launches Its Scientific Advisory Board

Marketwired May 31, 2017

BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer

Marketwired May 8, 2017

BriaCell Closes CEO Equity Investment

Marketwired March 24, 2017

BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax(TM) in Patients with Advanced Breast Cancer

Marketwired March 15, 2017

BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms

Marketwired March 7, 2017

BriaCell CEO Equity Investment Advances Company's Lead Cancer Product and Pipeline Expansion

Marketwired February 27, 2017

BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax(TM) in Advanced Breast Cancer

Marketwired February 6, 2017

BriaCell Closes Oversubscribed Non-Brokered Private Placement

MarketWire Canada August 19, 2016